Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol is a typical antipsychotic of the thioxanthene class. Melitracen is a tricyclic antidepressant (TCA). This combination is used for the treatment of anxiety and depression.
## Primary Indications
* Anxiety
* Depression
* Anhedonia
* Psychosomatic disorders
## Adult Dosing
* **Typical starting dose:** 1 tablet (flupentixol 0.5 mg, melitracen 10 mg) two to three times daily.
* **Maintenance dose:** Doses may be adjusted based on individual response.
* **Maximum dose:** 2 tablets three times daily (flupentixol 3 mg, melitracen 30 mg daily).
Dosing will depend on local protocols and individual patient response.
## Pediatric Dosing
Information on pediatric use is limited. Use is generally not recommended in children.
## Dose Adjustments
* **Hepatic impairment:** Use with caution. No specific dose adjustments are established.
* **Renal impairment:** Use with caution. No specific dose adjustments are established.
* **Elderly:** May be more sensitive to side effects; consider a lower starting dose.
## Contraindications
* Hypersensitivity to flupentixol, melitracen, or other thioxanthenes/TCAs.
* Recent myocardial infarction.
* Circulatory collapse, coma.
* Uncontrolled glaucoma.
* Concurrent use with MAOIs or within 14 days of discontinuing MAOIs.
## Adverse Effects
* **Common:** Sedation, dry mouth, constipation, blurred vision, dizziness, headache, insomnia, tremors, tachycardia, sweating.
* **Less common/Serious:** Orthostatic hypotension, extrapyramidal symptoms (EPS), anticholinergic effects (urinary retention, blurred vision, constipation), cardiac arrhythmias, seizures, weight gain, blood dyscrasias, neuroleptic malignant syndrome (NMS).
## Key Drug Interactions
* **MAOIs:** Risk of hypertensive crisis or serotonin syndrome. Avoid coadministration.
* **Central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids):** Increased CNS depression.
* **Anticholinergic drugs:** Potentiated anticholinergic effects.
* **Antihypertensives:** Flupentixol may reduce the effect of some antihypertensives.
* **CYP1A2, CYP2D6, CYP3A4 inhibitors/inducers:** May alter flupentixol and melitracen levels.
## Monitoring
* **Mental status:** Efficacy and adverse effects.
* **Vital signs:** Blood pressure (especially orthostatic), heart rate.
* **ECG:** Especially in patients with cardiovascular risk factors.
* **Signs of EPS:** Monitor for parkinsonism, akathisia, dystonia.
* **Signs of NMS:** Fever, rigidity, altered mental status, autonomic instability.
* **Liver function tests:** If liver impairment is suspected.
## Clinical Pearls
* This combination may offer synergistic benefits for patients with comorbid anxiety and depression.
* Due to anticholinergic and sedative effects, caution is advised when driving or operating machinery.
* ECT may be considered if clinical response is inadequate.
* Abrupt discontinuation should be avoided; taper dose gradually.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines before making any clinical decisions. Local formularies and prescribing guidelines may differ.
